Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers
Results
Phase 3
This trial compared chemotherapy with osimertinib as a second treatment for non small cell lung cancer.
The trial was for people with non small cell lung cancer (NSCLC) that had:
spread elsewhere in the body (advanced cancer)
got worse despite having a type of drug called a
The trial was open for people to join between 2014 and 2015. Researchers published the results in 2017.
Recruitment start: 1 August 2014
Recruitment end: 1 September 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Fiona Blackhall
AstraZeneca
Experimental Cancer Medicine Centre (ECMC)
Last reviewed: 12 December 2019
CRUK internal database number: 12536
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
